Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2021-04-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
第四届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Tianjin Ruipu Biotechnology Co., Ltd. It includes approvals of various proposals related to a specific private placement of shares, adjustments to the issuance plan, feasibility reports, impact analysis on financial indicators, and related party transactions. The document also mentions the convening of an extraordinary general meeting to approve certain matters. The content focuses on board decisions and corporate governance matters related to capital raising and share issuance, rather than presenting financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal board/management announcement about decisions made by the board, including management proposals and approvals. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it contains substantive board resolutions, not just a report publication announcement or a brief notice.
2021-04-21 Chinese
2021年度向特定对象发行股票募集资金使用的可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Tianjin Ringpu Biotechnology Co., Ltd. regarding a planned private placement of shares to raise funds. It extensively discusses the use of the raised capital, including investment projects, background, necessity, feasibility, and impact on the company's operations and financials. The content focuses on capital raising and financing activities, including detailed investment plans and financial projections related to the issuance of new shares to specific investors. There is no indication that this is an annual report, earnings release, or other types of filings. The document is not a brief announcement but a comprehensive feasibility analysis report related to a capital raising event. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement but a substantive report on financing plans.
2021-04-21 Chinese
2020年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2020 annual equity distribution (dividend payment) by Tianjin Ruipu Biotechnology Co., Ltd. It details the dividend amount, the basis of distribution, the record date, ex-dividend date, and other procedural information related to the dividend payment. It references the approval of the dividend plan at the 2020 annual general meeting and provides specifics on the cash dividend per share and related tax treatments. The document is not a full annual report or financial statement but a formal announcement of the dividend amount and payment details to shareholders. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters and contains detailed dividend information rather than just a brief mention or a link to a report, so it is not a Report Publication Announcement (RPA).
2021-04-15 Chinese
2021年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a "2021 First Quarter Performance Forecast" and contains preliminary estimated financial results for the period January 1 to March 31, 2021. It explicitly states that the results are unaudited and preliminary, and that detailed data will be disclosed in the company's first quarter report. The document is short (1559 characters) and serves as an earnings forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only, not a full interim report. Therefore, the document should be classified as an Earnings Release (ER). Q1 2021
2021-04-12 Chinese
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a repurchase and cancellation of restricted shares under a stock incentive plan. It details the number of shares repurchased, the reasons for repurchase, approvals from various board and shareholder meetings, and changes in share capital structure. The document is a formal announcement of a share repurchase and capital reduction, not a financial report or earnings release. It fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2021-04-08 Chinese
北京市康达律师事务所关于天津瑞普生物技术股份有限公司2020年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2020 Annual General Meeting (AGM) of Tianjin Ruipu Biotechnology Co., Ltd. It details the procedures of the AGM, the qualifications of attendees, the voting process, and the voting results on various proposals including approval of the 2020 annual report, financial statements, profit distribution, and share issuance plans. The document is not the actual annual report or financial statements but a legal opinion on the validity and legality of the AGM process and voting results. This type of document corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of the AGM. The document length is substantial and contains detailed voting results, not just a brief announcement or a certification letter, so it is not RPA or RNS. Therefore, the correct classification is DVA with high confidence.
2021-04-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.